Rivaroxaban News and Research

RSS
Normal coagulation tests used to check for side effect of internal bleeding may not be reliable

Normal coagulation tests used to check for side effect of internal bleeding may not be reliable

Instrumentation Laboratory announces European release of HemosIL Rivaroxaban Testing Solution

Instrumentation Laboratory announces European release of HemosIL Rivaroxaban Testing Solution

More people turn to popular new blood thinners for atrial fibrillation treatment

More people turn to popular new blood thinners for atrial fibrillation treatment

Alternative approach to treat fatal blood clots found to be more effective in patients

Alternative approach to treat fatal blood clots found to be more effective in patients

Newer anticoagulant medication may increase risk of GI bleeding in older patients

Newer anticoagulant medication may increase risk of GI bleeding in older patients

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Studies presented at ASH meeting compare new, standard-of-care treatments for blood clots

Studies presented at ASH meeting compare new, standard-of-care treatments for blood clots

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

New guidance can help physicians determine best oral blood thinners for patients

New guidance can help physicians determine best oral blood thinners for patients

Digoxin drug increases risk of adverse cardiovascular events or sudden death

Digoxin drug increases risk of adverse cardiovascular events or sudden death

Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

New supplement covers current knowledge and methods for management of AAICH

New supplement covers current knowledge and methods for management of AAICH

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

AAN guideline suggests people with irregular heartbeat to take oral anticoagulants to prevent stroke

AAN guideline suggests people with irregular heartbeat to take oral anticoagulants to prevent stroke

New study guides clinicians and policy makers on cost-effectiveness of anticoagulant drugs

New study guides clinicians and policy makers on cost-effectiveness of anticoagulant drugs

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

NPS MedicineWise reiterates safety messages around newer oral anticoagulants

NPS MedicineWise reiterates safety messages around newer oral anticoagulants

August edition of NPS RADAR includes reviews for new medicines listed on PBS

August edition of NPS RADAR includes reviews for new medicines listed on PBS